Navigation Links
Temple researchers show targeted cancer drug may stunt heart's ability to repair itself
Date:11/6/2012

(Philadelphia, PA) Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.

Studying mice with the equivalent of a heart attack, researchers found that the drug sorafenib (Nexavar) which inhibits proteins called tyrosine kinase receptors (RTKs), and is used in kidney and liver cancer treatment can interfere with heart stem cell activity, affecting the heart's ability to repair itself after injury. The findings suggest that sorafenib and other similar drugs that target these kinds of protein receptors may raise the risk for heart attack for some cancer patients with underlying heart disease, as well as affect the heart's ability to repair damage. By understanding how these cancer drugs can affect the heart, scientists and clinicians may be able to devise new treatment strategies to lessen such potentially damaging effects of often vital cancer drugs.

"The goal is not to take the drug off of the market it's a very good and useful drug that cancer patients need. We're trying to understand how this cancer drug and others like it can affect the heart, and what types of individuals might be at risk for problems," said senior author Steven Houser, PhD, Professor and Chair of Physiology at Temple University School of Medicine and Director of Temple's Cardiovascular Research Center. "Our results are beginning to provide a clearer picture of some of the potential physiological mechanisms at play."

Dr. Houser, first author Catherine Makarewich, a graduate student, and their co-workers reported their findings November 5, 2012 at the Late-Breaking Basic Science Session at the American Heart Association's Scientific Sessions in Los Angeles.

Sorafenib is a member of a broad class of anticancer drugs called targeted therapies that halt cancer growth, rather than necessarily trying to eliminate the disease. Termed a "multi-kinase" inhibitor, sorafenib blocks t
'/>"/>

Contact: Steven Benowitz
steven.benowitz@tuhs.temple.edu
215-707-4784
Temple University Health System
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Penn-Temple team discovers gatekeeper for maintaining health of cell energy source
2. NIH awards $20 million over 5 years to train next generation of global health researchers
3. Researchers develop a new cell and animal model of inflammatory breast cancer
4. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
5. Researchers Find Gene Mutations That May Be a Key to Autism
6. Researchers find evidence of banned antibiotics in poultry products
7. NJ stroke researchers report advances in spatial neglect research at AAN Conference
8. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
9. Researchers Map Brain Regions Linked to Intelligence
10. Researchers ID Genes That May Determine Mental Illness
11. Researchers Develop Blood Test for Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 ... contains 15 seconds of unique footage that users can shrink and stretch in the ... and more. Users can customize color, brightness, scale, speed, range, and flare attributes with ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health ... and sell Arterosil and Arterosil HP, and that all claims and counterclaims have ... Health Sciences, LLC (VHS) in the United States District Court for the Southern ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 ... Zoo to celebrate children helping children, a thank you to the many creative ... have contributed to the United Methodist initiative to end malaria deaths. , The ...
(Date:8/28/2015)... ... , ... For Dallas, the time is nearing for the annual Heart Walk, ... , The American Heart Association hosts their well-known Heart Walk to raise money in ... difference can be made. Walkers can participate in the cause and someone can also ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, ... the “Music With A Mission” benefit concert in Mendon, IL. Held in the Show ... money to support music education programs in the underfunded local school districts of Mendon ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... July 12 Volunteers and staff of the,American Heart ... Michael E. DeBakey, who died yesterday at the age ... cardiovascular medicine and is,personally responsible for developing the field ... American Heart Association.,"He single-handedly started surgery of the aorta, ...
... Care for Military, Vets, All Americans, WASHINGTON, July ... joined with national leaders in offering,condolences to the family ... medical pioneer with long ties to the Department,of Veterans ... DeBakey,s skills as a surgeon and manager, along with ...
... meets with President Sirleaf while part of Mercy Ships Crew ... ... Recently returned from a week-long international humanitarian mission to support Mercy ... upcoming NFL training camp with an additional sense of purpose knowing ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a ... of venous reflux disease, announced,today the resignation of Kathleen ... served on VNUS, Board of Directors since April 1997 ... that funded the company during,its start-up activities. There are ...
... assessment tool, SNPs made no difference, study finds , , ... predicting one,s chances of developing breast cancer do not ... some genetic markers for the disease, a new report ... (SNPs) that indicate a small but statistically significant increase ...
... $850 million in cuts, WASHINGTON, July 11 ... important benefits and pay more out of,pocket for ... Medicare,Advantage plan altogether under legislation approved this week ... would cut nearly $14 billion from the,Medicare Advantage ...
Cached Medicine News:Health News:American Heart Association Saddened by Death of Surgical Pioneer Michael E. DeBakey 2Health News:Redskins' Draft Pick Malcolm Kelly Energized By Trip To Mercy Ship In Liberia 2Health News:Redskins' Draft Pick Malcolm Kelly Energized By Trip To Mercy Ship In Liberia 3Health News:VNUS Medical Technologies, Inc. Announces Board of Director Resignation 2Health News:Recent Genetic Discoveries Don't Improve Prediction of Breast Cancer 2Health News:Pennsylvania Seniors' Medicare Advantage Benefits at Risk 2
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
(Date:8/28/2015)... , August 28, 2015 The ... Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ( ... Asia-Pacific , and Rest of the World) ... The global market for Eubiotics was valued at USD 4.62 ... Billion by 2020, at a CAGR of 7.4% from 2015 ...
(Date:8/27/2015)... 2015  The Academy of Managed Care Pharmacy ... (FDA,s) draft guidance and proposed rule that calls ... bear a nonproprietary name with an FDA-designated suffix. ... decision from the FDA on the naming issue ... urging the agency to use the same nonproprietary ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... Inc., announced today that it has successfully completed a ... Capital on behalf of the MPM Bio IV NVS ... reserves by entering into an agreement with Novartis International ... option to acquire Aires following the successful completion of ...
... Colorectal cancer (CRC) are two words that most people ... 50,000 Americans every year, the disease takes their life. Colorectal ... figure that may dramatically decrease if Americans are regularly screened ... one of the most curable cancers. The U.S. ...
Cached Medicine Technology:Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company 2New Screening Approach FIT to Fight Colorectal Cancer in the U.S. 2New Screening Approach FIT to Fight Colorectal Cancer in the U.S. 3New Screening Approach FIT to Fight Colorectal Cancer in the U.S. 4New Screening Approach FIT to Fight Colorectal Cancer in the U.S. 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: